Neoadjuvant chemotherapy with trastuzumab docetaxel and carboplatin administered every 3 weeks for Japanese women with HER2-positive primary breast cancer: efficacy and safety

摘要

BackgroundThis phase II neoadjuvant study evaluated the efficacy and safety of a triweekly regimen of docetaxel and carboplatin in combination with trastuzumab (TCbH) in Japanese women with human epidermal growth factor receptor type2 (HER2)-positive primary breast cancer.